Welcome to our dedicated page for Profusa news (Ticker: PFSA), a resource for investors and traders seeking the latest updates and insights on Profusa stock.
Profusa, Inc. (Nasdaq: PFSA) is a commercial stage digital health and medical technology company based in Berkeley, California, focused on tissue-integrated biosensors and its Lumee Oxygen tissue monitoring platform. The Profusa news feed on this page aggregates company press releases and third-party coverage related to its technology, clinical studies, commercial partnerships and capital markets activity.
Readers can expect technology and clinical news about Lumee Oxygen tissue monitoring, including study results in peripheral artery disease (PAD) and critical limb threatening ischemia (CLTI). Profusa has reported pilot phase data from a U.S.-based clinical study showing that Lumee oxygen traces strongly correlated with transcutaneous partial pressure of oxygen and that sensors remained functional for up to one year without sensor placement-related adverse events. News items also cover presentations at major vascular conferences such as Paris Vascular Insights and the Leipzig Interventional Course (LINC), where Profusa discusses additional insights into tissue oxygen monitoring.
The PFSA news stream also highlights commercial and distribution developments. Profusa has announced distributor partnerships in European markets for Lumee Oxygen tissue monitoring, including agreements intended to cover significant portions of the European Union population and to serve hospital and outpatient wound care settings. Additional releases describe collaborations with leading vascular surgeons and vascular centers in France and Greece, where Lumee technology is being adopted in clinical practice and clinical studies.
Investors will find corporate and financing updates in Profusa’s news, including details on its business combination with NorthView Acquisition Corporation, recapitalization efforts, senior secured convertible notes, and equity line of credit arrangements. The company has also outlined its own revenue targets and commercialization timelines in press releases, along with manufacturing milestones such as completion of sensor production runs and engagement of contract manufacturers for Lumee components.
By following this PFSA news page, users can track how Profusa communicates progress on its Lumee Oxygen platform, clinical validation, European commercialization plans, and balance sheet restructuring, as disclosed through its public announcements.
Profusa (NASDAQ: PFSA), a digital health company, has provided a comprehensive business update following its recent Nasdaq listing on July 14, 2025. The company outlined five strategic pillars: revenue growth, AI infrastructure, clinical/regulatory pathways, financial structure, and operational scale.
Key developments include: $100 million ELOC facility secured for growth funding, planned European launch of Lumee™ platform for tissue oxygen monitoring in Q1 2026, targeting a $10 billion global addressable market. The company aims for U.S. FDA submission mid-2026 with commercialization expected in 2027. Their glucose monitoring platform, addressing a 500 million patient market, is progressing with human validation data expected from EU and APAC clinical sites, targeting commercialization by mid-2027.
Profusa (NASDAQ: PFSA), a digital health company, has signed a Letter of Intent (LOI) for a distribution agreement with Dismeval, S.L. to market its Lumee Oxygen platform in Spain, including the Canary and Balearic Islands.
The partnership marks Profusa's first step in building its European distribution infrastructure. The company targets a $10.5B+ global addressable market for its tissue oxygen technology across three key indications: peripheral artery disease, chronic wounds, and critical limb ischemia. The European market presents significant potential with over 300,000 endovascular procedures annually.
Profusa (NASDAQ: PFSA), a commercial stage digital health company, has announced its initial $1 million investment in Bitcoin (BTC) as part of its digital asset treasury strategy. The company has partnered with BlockFills, a global crypto trading solutions provider, to execute its BTC treasury management strategy.
The investment represents Profusa's strategic move to hedge against macroeconomic uncertainties, reflecting its conviction in Bitcoin as a digital store of value. The company is collaborating with Ascent Partners Fund to establish a cost-efficient Bitcoin treasury strategy while maintaining sufficient capital for its AI-driven digital health platform development.
Profusa (NASDAQ: PFSA), a digital health company, has announced a significant Bitcoin treasury strategy through a $100 million equity line of credit (ELOC) with Ascent Partners Fund LLC. Under the agreement, Profusa will be able to sell its common stock to Ascent at 97% of the lowest VWAP in the 5 trading days following each put.
The company will use 100% of the net proceeds to purchase Bitcoin when its cash balance exceeds $5 million. Each put is limited to the lower of $5 million or 100% of the average daily traded value. The agreement includes issuing cashless warrants for 900,000 shares at $0.01 per share to Ascent, with total share issuance limited to 19.9% pending shareholder approval.
Profusa (NASDAQ:PFSA), a commercial stage digital health company, has completed its business combination with NorthView Acquisition Corp (NVAC). The company's common stock will begin trading on Nasdaq under the ticker "PFSA" on July 14, 2025.
The combined company secured $9 million through a secured convertible promissory note from an institutional investor, with potential access to up to $20 million under the convertible note facility. The funds will support transaction costs and working capital needs.
Profusa specializes in tissue-integrating biosensors that can monitor body chemistry continuously, transmitting data to smartphone applications and utilizing AI technologies for health management, particularly focusing on conditions like diabetes, critical limb ischemia, and peripheral arterial disease.